Previous 10 | Next 10 |
New responses in ovarian and urothelial cancers increase ORR to 52% from 44% in heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers after single dose of ADP-A2M4CD8 Across the entire ongoing Phase 1 SURPASS trial, the ORR has increased to 37%...
Adaptimmune ( NASDAQ: ADAP ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open. The consensus EPS Estimate is -$0.28 (-460.0% Y/Y) and the consensus Revenue Estimate is $4.97M (+314.2% Y/Y). Over the last 3 months, EPS estimates ...
Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 27, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2022, be...
Summary The second patient death prompted Alpine to terminate any future development of davoceticept. It's prudent that Alpine stopped unfruitful developments early on to focus on lower-hanging fruits. Next year, Alpine is poised to run basket studies on ALPN303 which can move...
Adaptimmune Therapeutics ( NASDAQ: ADAP ) on Tuesday said that GSK ( NYSE: GSK ) was transferring back cancer therapy programs NY-ESO and PRAME. In 2014 the two companies signed a collaboration and license agreement, for up to five programs. In 2017, ...
Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 – GSK to deliver data from the ongoing Phase 2 / potential registrational trial with lete-cel in sarcoma with final readouts expected in late 2023 – Adaptimmune will continue t...
Summary Adaptimmune Therapeutics plans to file a BLA this year. Despite that, the stock remains depressed. Their cash position is difficult as well. For further details see: Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this event. For further details see: Adaptimmune Therapeutics (ADAP) Presents At ESMO Congress 2022 - Slideshow
U.K.-based biotech Adaptimmune Therapeutics plc ( NASDAQ: ADAP ) announced new data Friday from its Phase 1 SURPASS trial for anti-cancer agent ADP-A2M4CD8 in patients with solid tumors. The data will be part of a presentation at the European Society for Medical Oncology (ES...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma pa...
2024-05-31 16:15:02 ET Wells Fargo analyst issues EQUAL-WEIGHT recommendation for ADAP on May 31, 2024 02:43PM ET. The previous analyst recommendation was Equal-Weight. ADAP was trading at $1.135 at issue of the analyst recommendation. The overall analyst consensus : BUY...